Annual EBITDA
-$47.41 M
+$3.20 M+6.32%
December 31, 2023
Summary
- As of February 7, 2025, GRTX annual EBITDA is -$47.41 million, with the most recent change of +$3.20 million (+6.32%) on December 31, 2023.
- During the last 3 years, GRTX annual EBITDA has risen by +$21.58 million (+31.28%).
- GRTX annual EBITDA is now -101.30% below its all-time high of -$23.55 million, reached on December 31, 2018.
Performance
GRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$5.78 M
-$1.72 M-42.41%
September 1, 2024
Summary
- As of February 7, 2025, GRTX quarterly EBITDA is -$5.78 million, with the most recent change of -$1.72 million (-42.41%) on September 1, 2024.
- Over the past year, GRTX quarterly EBITDA has dropped by -$1.11 million (-23.83%).
- GRTX quarterly EBITDA is now -42.41% below its all-time high of -$4.06 million, reached on June 30, 2024.
Performance
GRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$18.88 M
+$7.20 M+27.60%
September 1, 2024
Summary
- As of February 7, 2025, GRTX TTM EBITDA is -$18.88 million, with the most recent change of +$7.20 million (+27.60%) on September 1, 2024.
- Over the past year, GRTX TTM EBITDA has increased by +$28.53 million (+60.18%).
- GRTX TTM EBITDA is now -258.11% below its all-time high of -$5.27 million, reached on September 30, 2018.
Performance
GRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GRTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | -23.8% | +60.2% |
| 3 y3 years | +31.3% | -23.8% | +60.2% |
| 5 y5 years | -101.3% | -23.8% | +60.2% |
GRTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +34.7% | -42.4% | +64.5% | at high | +74.0% |
| 5 y | 5-year | at high | +34.7% | -42.4% | +72.5% | at high | +75.6% |
| alltime | all time | -101.3% | +34.7% | -42.4% | +72.5% | -258.1% | +75.6% |
Galera Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.78 M(+42.4%) | -$18.88 M(-27.6%) |
| Jun 2024 | - | -$4.06 M(-7.2%) | -$26.07 M(-32.0%) |
| Mar 2024 | - | -$4.37 M(-6.3%) | -$38.31 M(-19.2%) |
| Dec 2023 | -$47.41 M(-6.3%) | -$4.67 M(-64.0%) | -$47.41 M(-14.8%) |
| Sep 2023 | - | -$12.97 M(-20.4%) | -$55.65 M(+0.4%) |
| Jun 2023 | - | -$16.30 M(+21.0%) | -$55.44 M(+8.8%) |
| Mar 2023 | - | -$13.47 M(+4.3%) | -$50.97 M(+0.7%) |
| Dec 2022 | -$50.61 M(-30.3%) | -$12.91 M(+1.2%) | -$50.61 M(-2.2%) |
| Sep 2022 | - | -$12.76 M(+7.9%) | -$51.73 M(-12.6%) |
| Jun 2022 | - | -$11.83 M(-9.8%) | -$59.16 M(-13.4%) |
| Mar 2022 | - | -$13.11 M(-6.6%) | -$68.31 M(-5.9%) |
| Dec 2021 | -$72.56 M | -$14.03 M(-30.5%) | -$72.56 M(-6.1%) |
| Sep 2021 | - | -$20.19 M(-3.8%) | -$77.26 M(+6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$20.98 M(+20.9%) | -$72.81 M(+5.4%) |
| Mar 2021 | - | -$17.36 M(-7.3%) | -$69.10 M(+0.2%) |
| Dec 2020 | -$68.99 M(+41.8%) | -$18.73 M(+19.0%) | -$68.99 M(+4.7%) |
| Sep 2020 | - | -$15.75 M(-8.8%) | -$65.92 M(+5.4%) |
| Jun 2020 | - | -$17.27 M(+0.1%) | -$62.53 M(+11.6%) |
| Mar 2020 | - | -$17.24 M(+10.1%) | -$56.02 M(+15.2%) |
| Dec 2019 | -$48.64 M(+106.5%) | -$15.66 M(+26.8%) | -$48.64 M(+17.6%) |
| Sep 2019 | - | -$12.36 M(+14.9%) | -$41.36 M(+20.7%) |
| Jun 2019 | - | -$10.76 M(+9.0%) | -$34.27 M(+45.7%) |
| Mar 2019 | - | -$9.86 M(+17.7%) | -$23.52 M(+72.2%) |
| Dec 2018 | -$23.55 M(-1.1%) | -$8.38 M(+59.1%) | -$13.65 M(+159.1%) |
| Sep 2018 | - | -$5.27 M | -$5.27 M |
| Dec 2017 | -$23.82 M | - | - |
FAQ
- What is Galera Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Galera Therapeutics?
- What is Galera Therapeutics annual EBITDA year-on-year change?
- What is Galera Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Galera Therapeutics?
- What is Galera Therapeutics quarterly EBITDA year-on-year change?
- What is Galera Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Galera Therapeutics?
- What is Galera Therapeutics TTM EBITDA year-on-year change?
What is Galera Therapeutics annual EBITDA?
The current annual EBITDA of GRTX is -$47.41 M
What is the all time high annual EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high annual EBITDA is -$23.55 M
What is Galera Therapeutics annual EBITDA year-on-year change?
Over the past year, GRTX annual EBITDA has changed by +$3.20 M (+6.32%)
What is Galera Therapeutics quarterly EBITDA?
The current quarterly EBITDA of GRTX is -$5.78 M
What is the all time high quarterly EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high quarterly EBITDA is -$4.06 M
What is Galera Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GRTX quarterly EBITDA has changed by -$1.11 M (-23.83%)
What is Galera Therapeutics TTM EBITDA?
The current TTM EBITDA of GRTX is -$18.88 M
What is the all time high TTM EBITDA for Galera Therapeutics?
Galera Therapeutics all-time high TTM EBITDA is -$5.27 M
What is Galera Therapeutics TTM EBITDA year-on-year change?
Over the past year, GRTX TTM EBITDA has changed by +$28.53 M (+60.18%)